Great Basin Granted European Patent Protection

Patent protection for on-chip amplification safeguards Company’s technology in European Union

SALT LAKE CITY -- Great Basin Scientific, Inc. (NASDAQ: GBSN, GBSNU), a molecular diagnostics company, announced today the European Patent Office has issued a notice to allow for application (#09711952.3) for the Company’s on-chip amplification technology, currently patented in the U.S.

This newly allowed patent further enhances protections for the Company's patent portfolio, and follows the U.S. patent (8,637,250, issued Jan. 28, 2014) for the same technology for point-of-care isothermal amplification and detection of polynucleotides on the surface of modified silicon chips. This patent drives technology behind future simplification of the chip technology, fully integrating sample preparation, amplification, and detection to provide faster results at a lower cost, asserts Great Basin.

Published: 16 June 2015

Written by Editor

Sunesis Pharmaceuticals Presents New Data From VALOR Evaluating Vosaroxin in Older Patients With Acute Myeloid Leukemia at the 20th Congress of the European Hematology Association

Sunesis to Host Conference Call and Webcast Today at 10:00 AM Eastern Time

SOUTH SAN FRANCISCO, Calif., June 12, 2015 -- Sunesis Pharmaceuticals, Inc. (SNSS) announced today additional results of the VALOR trial, a Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory acute myeloid leukemia (AML). The results are being presented today, Friday, June 12^th from 5:15 p.m. to 6:45 p.m. Central European Time at the acute myeloid leukemia (AML) poster session of the 20^th Congress of the European Hematology Association (EHA) taking place in Vienna, Austria.

VALOR is a randomized, double-blind, placebo-controlled Phase 3 trial which enrolled 711 adult patients with first relapsed or refractory AML at 124 leading sites in 15 countries. Patients were stratified for age, geographic region and disease status and randomized one to one to receive either vosaroxin and cytarabine or placebo and cytarabine.

Published: 12 June 2015

Written by Editor

Nasdaq Up on News Project Update

Discovery Ventures Announces Definitive Agreement for $7 Million

VANCOUVER, BRITISH COLUMBIA--Jun 10, 2015) - Discovery Ventures Inc. ("Discovery") (TSX VENTURE:DVN)(0DV.F)(DTVMF) is pleased to announce that it has entered into a definitive agreement with Dan Omeniuk (the "Investor") whereby the Investor has agreed to provide two secured credit facilities to Discovery: a $2 million convertible credit facility (the "Convertible Credit Facility") and a $5 million credit facility (the "Credit Facility", together with the Convertible Credit Facility, the "Credit Facilities").

Any funds drawn down on the Convertible Credit Facility will be convertible at the option of Discovery or the Investor into units (each, a "Unit") of Discovery at a price of $0.10 per Unit. Each Unit will consist of one common share of Discovery (each, a "Share") and one warrant, with each warrant entitling the Investor to purchase an additional Share at a price of $0.15 per Share for a period of 3 years. Any conversion that would result in the Investor owning more than 20% of the issued and outstanding shares of Discovery would be subject to Discovery obtaining shareholder approval of the Credit Facilities.

Published: 10 June 2015

Written by Editor

Actinium Announces Closing of $5 Million Registered Direct Offering of Common Stock

NEW YORK, NY--(Marketwired - June 09, 2015) - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the closing of its previously announced registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company's common stock at a purchase price of $2.60 per share. This financing was led by investor Dr. Phillip Frost.

Actinium anticipates using the net proceeds for general corporate purposes, including capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs.

Published: 10 June 2015

Written by Editor

Nasdaq Up on News Financing

Ivanhoe Mines and China's Zijin Mining Group Sign Landmark Agreement to Co-Develop the World-Scale Kamoa Copper Discovery in the Democratic Republic of Congo

Zijin to acquire 49.5% of Ivanhoe's Kamoa stake for a total cash consideration of US$412 million Zijin holds option to acquire an additional 1% share upon successfully arranging project financing for 65% of the first phase of Kamoa's development costs

XIAMEN, CHINA--(May 26, 2015) - Robert Friedland, Executive Chairman of Ivanhoe Mines Ltd. (IVN.TO), and Lars-Eric Johansson, Chief Executive Officer, announced today that Ivanhoe and Zijin Mining Group Co., Ltd. have agreed to a strategic co-development of the Kamoa copper discovery in the Democratic Republic of Congo.

Published: 26 May 2015

Written by Editor

TSX Up on News Project Update

Great Basin Scientific Inc ( GBSN )

Great Basin Granted European Patent Protection

Sunesis Pharmaceuticals Inc ( SNSS )

Sunesis Pharmaceuticals Presents New Data From VALOR Evaluating Vosaroxin in Older Patients With Acute Myeloid Leukemia at the 20th Congress of the European Hematology Association

Discovery Ventures Inc ( DVN )

Discovery Ventures Announces Definitive Agreement for $7 Million

Actinium Pharmaceuticals Inc ( ATNM )

Actinium Announces Closing of $5 Million Registered Direct Offering of Common Stock

Ivanhoe Mines Ltd ( IVN )

Ivanhoe Mines and China's Zijin Mining Group Sign Landmark Agreement to Co-Develop the World-Scale Kamoa Copper Discovery in the Democratic Republic of Congo